AI assistant
Jazz Pharmaceuticals plc — Director's Dealing 2013
Jan 16, 2013
30751_dirs_2013-01-16_be054652-dbb0-407f-8939-ebc1fa362e6f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2013-01-15
Reporting Person: ENRIGHT PATRICK G (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2013-01-15 | Ordinary Shares | S | 22772 | $56.7218 | Disposed | 1618300 | Indirect |
| 2013-01-15 | Ordinary Shares | S | 456 | $56.7215 | Disposed | 32442 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Ordinary Shares | 2250 | Direct |
Footnotes
F1: Securities were sold pursuant to a 10b5-1 trading plan.
F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.50 to $57.13, inclusive. The reporting person undertakes to provide to Jazz Pharmaceuticals plc, any security holder of Jazz Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.50 to $57.13, inclusive. The reporting person undertakes to provide to Jazz Pharmaceuticals plc, any security holder of Jazz Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4: The reporting person disclaims beneficial ownership of the securities of Jazz Pharmaceuticals plc held by Longitude Venture Partners, L.P. and Longitude Capital Associates, L.P., except to the extent of his pecuniary interest therein.
F5: These restricted stock units were granted pursuant to Jazz Pharmaceuticals plc's 2007 Equity Incentive Plan on August 9, 2012. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units will vest in full on August 9, 2013.